anonymous
Guest
anonymous
Guest
This is not a question of if there is emerging resistance, but when. See when resistance emerges to a 3 drug regimen, a practitioner knows that there was nothing different they could have done. When the same thing happens to a 2DR... well that is a different story. If a patient asks "Hey doc, but you said this is better for me and now you are telling me we have to change. How did that happen?" that will be pretty much the end of 2DR at that office.In medicine, anytime you can achieve comparable efficacy results with similar or less adverse effects, you always choose less medication. ALWAYS! At least that is what is taught in medical school. If Dovato can continue to demonstrate low or no resistance over time, the mindset will shift. It all has to do with how DTG is designed and how effective it truly is. Now, will the market take note of what I mentioned? That is a different story. I predict that this division will be a "portfolio" of medications to help with our motto of no HIV patient left behind. We will continue to generate billions in sales and will be very profitable for GSK as a whole. The question becomes, how many reps are needed? How many RSDs are needed? In two years we will have a better picture. For now, continue to know that we have a great set of medications to promote. If you feel differently, you should go work for another company. No one is holding you here. You are free to leave at any time. Best of luck to all!
The whole 2DR edifice is built on the tenuous contention that there will be little to no emergent resistance. Resistance *always* emerges, the question is are you using the gold standard so that you can honestly say you couldn't have done anything more. The shot will be the most interesting play by far. It will demonstrate just how spectacularly wrong and out of touch the decision to venture into long acting was. "Hey doc can I come to your office monthly to have two injections, one in each buttock, instead of taking one pill once a day?" said no patient ever.